Phaseline

Companies › Rapport Therapeutics

Rapport Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Neurology, Psychiatry; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RAP-219
GABA-A positive allosteric modulator
GABRAPhase 3Focal Seizure; Bipolar 1 Disorder; Focal Epilepsy; EpilepsyJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07046494RAP-219Phase 2Bipolar 1 DisorderPsychiatryAug 2026
NCT07923097RAP-219Phase 1EpilepsyNeurologyJun 2027
NCT07219407RAP-219Phase 2Focal EpilepsyNeurologyFeb 2028
NCT07594119RAP-219Phase 3Focal SeizureNeurologyJul 2029
NCT07563881RAP-219Phase 3Focal SeizureNeurologyJul 2029

From the company's SEC filings

Cash and short-term investments of $395m on 2026-09-30; operating cash outflow about $129m a year; runway about 37 months at that burn, to Oct 2029; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GABRA (1)

Companies with the same targets

–

Companies built like this

Lipocine Xenon Pharmaceuticals Sichuan Jishengtang Pharmaceutical Impax Laboratories Intra-Cellular Therapies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.